Adenosine (A) to inosine (I) RNA editing, is a hydrolytic deamination reaction catalyzed by 28 adenosine deaminase (ADAR) acting on RNA enzymes. RNA editing is a molecular process that 29 involves the post-transcriptional modification of RNA transcripts. Interestingly, few studies have 30 been carried out to determine the role of RNA editing in vascular disease. The current study 31 found that in blood samples positive for congenital heart disease (CHD) ADAR1 and ADAR2 32 expression change at RNA level was opposite to each other. That is, an increase of ADAR1 33 mRNA was noticed in human CHD cases, whereas ADAR2 mRNA was vastly down-regulated.
Introduction
level but no prominent difference in ADAR1 expression. Moreover, they showed high editing of 85 MED13 in cyanotic CHD cases as opposed to acyanotic CHD patients (13) . Recent study has 86 shown an increase in expression of a lysosomal cysteine protease encoded by cathepsin S RNA 87 (CTSS) via ADAR1 mediated RNA editing followed by HuR recruitment . Cathepsin S has a 88 role in vascular inflammatory processes and the CTSS mRNA editing is increased in hypoxic or 89 pro-inflammatory conditions as wells as in patients suffering from clinical or subclinical vascular 90 damage (14) . 91 In the current study we have determined the RNA level of ADAR1 and ADAR2 in congenital 92 heart disease patients. We also checked the relative gene expression of FoxP1 which is an 93 important transcription factor crucial for angiogenesis. We found a strong down-regulation of 94 ADAR2 and an up-regulation of ADAR1. Interestingly, microarray data analysis of human non-95 ischemic myocardial tissues showed similar trend. Interestingly the ischemic myocardial tissues 96 showed completely opposite trend. To further explore the role of ADAR2 in heart physiology, 97 we used ADAR2 knockout mouse. Although no strong anomaly in heart physiology was 98 observed as documented previously (15) The Adar2 −/− knockout mouse was a kind gift of Peter Seeburg. These transgenic mice are in an 143 SV129 background. As ADAR2 deficiency leads to early postnatal lethality, the mice were 144 rescued with a pre-edited Gria2 receptor (Gria2 R/R ) (18, 19) . Mice were bred in Vienna Biocentre Agilent QPCR NGS library quantification kit. Cluster generation and sequencing was carried out 159 using the Illumina Genome Analyzer IIx system according to the manufacturer's guidelines.
160
Illumina sequencing was performed at the CSF NGS Unit (csf.ac.at). After sequencing at a read 161 length of 36 base pairs, adaptor sequences were removed using Cutadapt (22).
162
Mapping to mature miRNA sequences 163 Mapping of clipped reads to mature miRNA sequences was performed as described previously 164 Mapping was performed using NextGenMap, restricting the mapped reads to have at least 90% 165 identity (# differences/alignment length) (23). 168 RNA was extracted from 35 affected congenital heart disease patients and 13 normal individuals 169 were taken as control. Most of the patients had VSD (Ventricular septal defects). All CHD 170 samples were pre-operative cases. Since recent reports indicated, that RNA editing might be 171 involved in cardiogenisis (13, 14) . We checked the expression of the functional RNA editing 172 enzymes using quantitative realtime PCR (qPCR). A significant decline in ADAR2 expression 173 was observed. However, on the contrary, ADAR1 showed a significant increase ( Figure 1a ). The 174 observed elevated ADAR1 expression is in line with the recent finding demonstrating higher 175 ADAR1 expression in the human patients undergoing carotid endarterectomy operation (14). As a 176 control for CHD, we selected a member of fork head box family of transcription factor (FoxP1).
166

Results
167
ADAR2 has the lowest expression in CHD patients
177
FoxP1 has a critical role in murine as well as human heart development. It showed high 178 expression during embryonic stages as opposed to postnatal stage and is critical for 179 cardiomyocyte proliferation (24). We found a significant decrease in FoxP1 expression 180 confirming that the RNA extracted from the blood of CHD patients can depict the expression 181 differences between normal and patient samples. Surprisingly out of these three genes, ADAR2 Heart defect specific function 191 We further investigated whether this increase in ADAR1 is specific for a heart defect. As in our 192 study the patients were suffering from different forms of congenital heart disease. ADAR1 was 193 strongly up-regulated in ASD followed by VSD. However, it shows approximately 3fold 194 increase-in TOF and CAVSD (Figure 2a and d) . On the contrary, ADAR2 shows a strong 195 significant decline in CAVSD, TOF and VSD. (Figure 2b and d) . This specificity of gene 196 expression of ADAR1 and ADAR2 with heart defects can be answered by the differences in the Since increase in ADAR1 has been found in CHD patients. We determined whether this 260 observed increase in ADAR1 is due to deregulation of ADAR2. Therefore, we determined 261 ADAR1 level in the absence of ADAR2. We did not find any significant change in ADAR1 level 262 ( Figure 6 ). Therefore, we can conclude that the observed increase in ADAR1 is soley because of 263 the CHD defect. 
ADAR2 -/heart shows down-regulation of miR-29b 272
A previous study focusing on ADAR2 -/mice showed a statistically significant decrease in heart 273 rate (15). We performed RNA sequencing of ADAR2 -/mice heart samples in triplicates and 274 observed approximately ~2-fold decrease in miR-29b level consistently at P6 stage.
275
Approximately 1.5 fold down-regulation has been observed for miR451-b, miR451-a, miR19b, 276 (Table 1) . To our surprise, we did not observe any up-regulated miRNAs. Quantitative trait loci 
285
After miR-29b, miR-451(a and b), miR-19b1and different members of let-7, family also showed 286 down-regulation in ADAR2 knockout mice heart However, they showed significant but small 287 down-regulation of only about 1-1.5 fold ( Adenosine deamination by ADARs is a post-transcriptional event that can diversify the 298 transcripts both at sequence as well as structure level. The deregulation of editing has been 299 associated with number of diseases (8, 13, 33) .
300
ADARs play a significant role in development. Moreover the tissue and site specific editing 301 largely affects the differential expression of substrate transcripts (38, 39) . In our study, we found 302 a strong down-regulation of ADAR2 and a strong increase in ADAR1 in ASD and VSD patient 303 samples. This observation is in line with previous finding demonstrating increased CTSS mRNA 304 editing due to up-regulation of ADAR1 in human atherosclerotic plaques (14). Since the 305 expression analysis was performed only on the PBMCs from normal and CHD patients we 306 further extended our study to myocardial tissues. Expression analysis of myocardial tissues from 307 ischemic and non-ischemic patients showed a significant decline in ADAR2 expression level 308 (Figure 3 ). This result supported our finding that ADAR2 not only down-regulates in PBMCS 309 but also showed decreased expression in human cardiomyopathy tissues.
310
The stong downregulation of ADAR2 with respect to heart disease urged us to further explore 311 what heart related processes might be ADAR2 regulating? To address this query, we used 312 ADAR2 knock out mouse. We chose FLNB which plays an essential role in the heart however 313 lack of ADAR2 strongly decreased its editing. We did not observe any change in FLNB 314 expression in the absence of ADAR2. The increase on ADAR1 in the PBMCs and the 315 simultaneous downregulation of ADAR2 posed a question whether the observed effect is 316 because of ADAR2 or is it the consequence of CHD? We observed no significant change in 317 expression of the ADAR1 isoforms in the absence of ADAR2. This shows that CHD might be 318 triggering an inflammatory response leading to increase in ADAR1. The elevated ADAR1 319 expression in atherosclerosis has been documented previously (14) .
320
ADARs can modulate microRNA processing and also are capable of retargeting the microRNA 321 to different substrate (35). Like ADAR1, ADAR2 also can modulate microRNA processing.
322
Since a number of micro RNAs like miR-1, miR-423 are associated with heart disease we 323 thought of investigating the microRNA profile in ADAR2 knock out mouse heart (40).
324 Surprisingly, we did not observe any up-regulated micro RNAs in the ADAR2 -/mice heart. 325 However, we observed a decline of ~1.5-2 fold in miR-29b, miR-451, miR19 and members of let 326 -7 family (Table 1) . 
